NEW YORK, Oct. 20, 2016 -- FolioDynamix, a leading provider of wealth management technology and advisory services, announces the appointment of Dan Ciavarella as EVP, Product Management, to head the firm’s product management and development efforts. This new position represents an increased focus, of both attention and resources, on developing and distributing the solutions that help clients and prospect firms meet the new regulations and guidelines required by the DOL Fiduciary Rule. Dan will also focus more broadly on continued development of a more robust and digitally enhanced advisor/investor experience for the platform suite as a whole.
Dan, who was most recently at Cetera Financial Group, has a deep background in product strategy and wealth management and held leadership roles at Genworth Financial and 1st Global. Cetera has been taking an industry-leading role in developing tools, education, and resources to help advisors prepare for the DOLFiduciary Rule; Dan worked closely across management and with advisors to develop educational tools and business-at-risk assessments, and drove technology adoption and integration. Dan brings a client-centric approach to developing an end-to-end platform solution, and his perspective will help FolioDynamix continue to refine strategy and development.
The FolioDynamix solution—which pairs technology and advisory options—is based on the core FolioDynamix platform with key integration partners to help meet the new recordkeeping, recording, and best interest provisions of the Fiduciary Rule. Folio is a pioneer of the concept of “Fiborg Advisors”—those advisors who leverage technology to automate non-revenue-generating activities and maximize the time spent actively collaborating with, and working for, investors. This fiborg concept of maximizing technology is especially important in light of the new fiduciary rule requirements and has been fueling the firm’s development goals.
“The industry as a whole is going through a once-in-a-generation change—a fundamental shift in how business is done,” says Steve Dunlap, president of the firm. “Advisors will need technology to succeed, and it’s important to us to think strategically to deliver solutions ahead of client needs. Dan’s role will be to drive that strategic thinking and we’re glad to have him on board.”
About FolioDynamix
FolioDynamix is leading the evolution of the wealth management experience, with an end-to-end technology solution paired with a suite of advisory tools including model portfolios, research, and overlay management services. Through our powerful technology platform, advisors can manage the entire client lifecycle from proposal generation to account opening to account management (trading and rebalancing) to reporting, all through a sophisticated but easy-to-use cloud-based solution. FolioDynamix is an Actua company (Nasdaq:ACTA). Visit www.foliodynamix.com. Follow us on Twitter @foliodx.
Press Contact: Meghan McCartan +1 201-605-1926 [email protected]


FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 



